Analysts Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Price Target at $9.80

Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) have been assigned an average rating of “Moderate Buy” from the six brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $9.80.

ACRS has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, December 29th. Wall Street Zen downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Thursday. Finally, Craig Hallum began coverage on Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price target for the company.

Institutional Trading of Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. ProShare Advisors LLC acquired a new position in Aclaris Therapeutics during the 2nd quarter worth about $26,000. AXQ Capital LP bought a new stake in Aclaris Therapeutics during the 3rd quarter worth about $27,000. Police & Firemen s Retirement System of New Jersey acquired a new stake in Aclaris Therapeutics in the 2nd quarter valued at about $28,000. XTX Topco Ltd bought a new position in shares of Aclaris Therapeutics in the second quarter worth about $34,000. Finally, R Squared Ltd bought a new position in shares of Aclaris Therapeutics in the fourth quarter worth about $37,000. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Aclaris Therapeutics Stock Performance

Shares of NASDAQ ACRS opened at $3.69 on Friday. Aclaris Therapeutics has a 52-week low of $1.05 and a 52-week high of $4.89. The business has a fifty day moving average of $3.41 and a two-hundred day moving average of $2.77. The stock has a market cap of $445.01 million, a PE ratio of -6.96 and a beta of 0.88.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.01). Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%.The firm had revenue of $1.30 million for the quarter, compared to analyst estimates of $2.07 million. Analysts predict that Aclaris Therapeutics will post -0.82 earnings per share for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.